Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm - LARVOL DELTA

Cost-effectiveness analysis of larotrectinib vs standard of care for treatment of metastatic NTRK fusion colorectal cancer. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "The ICER of larotrectinib therapy vs regorafenib therapy or larotrectinib therapy vs trifluridine/tipiracil therapy was calculated at 23,321.46 USD/QALY or 22,585.39 USD/QALY. From the perspective of healthcare payers in China, larotrectinib was cost-effective compared to standard of care as a second-line treatment or subsequent treatment for advanced or metastatic CRC patients with NTRK gene fusion-positive."

HEOR • Journal • Colorectal Cancer • Oncology • Solid Tumor • NTRK

Prognostic impact of KRAS mutation subtypes in later-line metastatic colorectal cancer (ESMO Asia 2025) - "In Taiwanese mCRC patients treated with later-line regorafenib or trifluridine/tipiracil, KRAS mutation subtypes demonstrated distinct survival patterns. KRAS G12 mutations were associated with poorer OS, whereas Switch II mutations showed numerically longer OS. Codon- and region-based KRAS classification may provide prognostic insights for later-line therapy."

Metastases • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Fruquintinib combined with TAS-102 with or without SBRT as third- or later-line treatment in metastatic colorectal cancer : Preliminary results from a prospective phase II trial (ESMO Asia 2025) - P2 | "Fruquintinib combined with TAS-102 with or without SBRT showed promising preliminary efficacy and acceptable safety in third-or later-Line treatment in metastatic colorectal cancer, requiring confirmation in expanded studies."

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor

A systematic review of cost-effectiveness studies of later-line treatments for refractory metastatic colorectal cancer. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "Later-line treatments were generally not found to be cost-effective compared to BSC, mainly due to high drug costs. No treatment showed consistently favorable results across studies, with outcomes varying by comparator, country, and model settings."

HEOR • Journal • Review • Colorectal Cancer • Oncology • Solid Tumor

TAS-102 plus bevacizumab in refractory metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials with validation from prospective single-arm studies. (ASCO-GI 2026) - "The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • Retrospective data • Review • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Sequencing fruquintinib and trifluridine/tipiracil to improve outcomes in the real-world management of MMR-proficient, chemo-refractory colorectal cancer in Hong Kong. (ASCO-GI 2026) - "The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Real-world • Real-world evidence • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A phase II study of nanoliposomal irinotecan with TAS102 and bevacizumab for patients with refractory metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - P2 | "Funded by Ipsen Clinical Trial Registration Number: NCT05854498 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Trifluridine-tipiracil versus radioembolization for patients with refractory colorectal liver metastases: A real-world data analysis. (ASCO-GI 2026) - "The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Real-world • Real-world evidence • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Regorafenib combined with trifluridine/tipiracil versus regorafenib monotherapy in refractory metastatic colorectal cancer (FDZL-REGOT): A randomized phase 2 trial. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT05970705 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • Monotherapy • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Pooled analysis of individual patient data (IPD) from clinical trials of trifluridine/tipiracil (FTD/TPI) and bevacizumab (BEV) for metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - "Funded by Taiho Pharmaceutical Co., Ltd Clinical Trial Registration Number: UMIN000041621 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • Retrospective data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Real-world outcomes of trifluridine/tipiracil ± bevacizumab in refractory metastatic colorectal cancer: A SUNLIGHT validation study. (ASCO-GI 2026) - "The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Impact of codon-level KRAS mutations on response to TAS-102, TAS-102+bevacizumab, or regorafenib in metastatic colorectal cancer. (ASCO-GI 2026) - "Funded by University of Utah Translational Research: Implementation, Analysis, and Design (TRIAD) The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

Real-world clinical outcomes among metastatic colorectal cancer (mCRC) patients with liver metastases who received trifluridine/tipiracil (FTD/TPI) or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy. (ASCO-GI 2026) - "Funded by Taiho Oncology, Inc. The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Clinical data • Combination therapy • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study. (ASCO-GI 2026) - P2 | "Funded by Taiho , Eli Lilly Clinical Trial Registration Number: NCT04660760 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Combination therapy • Head-to-Head • Metastases • P2 data • Esophageal Adenocarcinoma • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Trifluridine/tipiracil and pembrolizumab combination as later-line treatment in patients with advanced gastric cancer: A multi-cohort phase II study with lead-in safety cohort (LonKey trial). (ASCO-GI 2026) - P1/2 | "Funded by MSD; JEIL Pharmaceutical Co., Ltd. Clinical Trial Registration Number: NCT05508737 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Efficacy and safety of trifluridine/tipiracil plus ramucirumab in advanced gastric cancer as third-line or later treatment: A multicenter phase II study. (ASCO-GI 2026) - "Clinical Trial Registration Number: jRCTs041210105 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

The primary results of a randomized phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus FTD/TPI for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG 15822G). (ASCO-GI 2026) - "Funded by TAIHO Phamaceutical Co., Ltd. Clinical Trial Registration Number: jRCTs041220120 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A multi-center phase 1b/2 clinical trial of concurrent administration of fruquintinib and FTD/TPI in patients with previously treated unresectable metastatic colorectal cancer and gastric cancer (FACT). (ASCO-GI 2026) - "Clinical Trial Registration Number: jRCT2031240630 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P1/2 data • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A phase 2 trial of TAS-102 with or without celecoxib in ctDNA-defined minimal residual disease (MRD) in colorectal cancer after completion of adjuvant chemotherapy. (ASCO-GI 2026) - P2 | "Funded by Taiho Oncology, Inc Clinical Trial Registration Number: NCT05343013 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Circulating tumor DNA • Clinical • Minimal residual disease • P2 data • Residual disease • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

FRUQUITAS: Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma (clinicaltrials.gov) - P3 | N=324 | Not yet recruiting | Sponsor: Federation Francophone de Cancerologie Digestive

New P3 trial • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor

A Phase II study of Trifluridine/Tipiracil (FTD/TPI) in Combination with Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction adenocarcinomas. (PubMed, Oncologist) - P2 | "The combination of ramucirumab and FTD/TPI demonstrated well-manageable safety profile. Our study did not meet primary endpoint. Ongoing clinical trials will help us understand if ramucirumab plus FTD/TPI is noninferior to ramucirumab/paclitaxel. The trial was registered at www.clinicaltrials.gov (NCT03686488)."

Journal • P2 data • Cardiovascular • Esophageal Cancer • Fatigue • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Hypertension • Neutropenia • Oncology • Pain • Solid Tumor

Baseline serum albumin level as a predictive factor for the efficacy of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a retrospective cohort study. (PubMed, J Pharm Health Care Sci) - No abstract available

Biomarker • Journal • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor

Efficacy and Safety of Tislelizumab in Combination with Trifluridine/Tipiracil and Bevacizumab as Third-Line or Beyond Therapy for Locally Advanced Unresectable or Metastatic MSS Colorectal Cancer [WITHDRAWN] (ESMO-IO 2025) - No abstract available

Clinical • Combination therapy • Metastases • Colorectal Cancer • Oncology • Solid Tumor

CombiCoR-Vax trial: Study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer (ESMO-IO 2025) - P2 | "This study explores a novel sequential immunochemotherapy approach combining a DC-based vaccine with anti-PD-1 immunotherapy and standard chemotherapy in patients with refractory pMMR/MSS mCRC. To the best of our knowledge, this is the only ongoing trial investigating this therapeutic combination in this specific patient population.Clinical trial identification NCT06522919.Legal entity responsible for the study IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy."

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • MSI

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial (clinicaltrials.gov) - P2 | N=236 | Not yet recruiting | Sponsor: Sun Yat-sen University

Head-to-Head • New P2 trial • Colorectal Cancer • Oncology • Solid Tumor